Page last updated: 2024-10-27

fluorouracil and Nervous System Disorders

fluorouracil has been researched along with Nervous System Disorders in 51 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)."9.17Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013)
"To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)."9.16A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."9.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
"5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients."9.08Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."7.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy."7.715-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."7.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."6.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
"Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP."6.72FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006)
"The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen."5.22Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016)
"Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)."5.17Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013)
"To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)."5.16A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."5.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
"5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients."5.08Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997)
"In an attempt to improve the primary treatment of malignant gliomas we used a concomitant 6-week course of chemoradiotherapy with 5 fluorouracil (5 FU) and hydroxyurea (HU) in 24 adults with anaplastic astrocytoma (AA) (7 cases) or glioblastomas (GLB) (17 cases)."5.07Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. ( Armand, JP; Cioloca, C; Constans, JP; Cvitkovic, FB; Haie-Meder, C; Maugis, N; Papadimitrakopoulou, V, 1993)
"Capecitabine is one of the most effective oral regimens of chemotherapy against advanced or recurrent breast cancer."3.74[Management of hand-foot syndrome in patient treated with capecitabine]. ( Anami, S; Fujii, C; Fujino, M; Fujita, M; Furukawa, H; Inoue, M; Kamigaki, S; Nakayama, T; Tatsuta, M; Yasui, Y, 2008)
"The purpose of this study is to determine the characteristic clinical features, radiologic findings, and precipitating and prognostic factors in the patients with breast cancer and with 5-Fluorouracil (5-FU)-induced leukoencephalopathy."3.715-fluorouracil-induced leukoencephalopathy in patients with breast cancer. ( Cho, KH; Choi, SM; Kim, BC; Kim, MK; Lee, SH; Yang, YS, 2001)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."3.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population."2.87Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. ( Andre, T; Boukovinas, I; Grothey, A; Iveson, T; Kerr, R; Labianca, R; Meyerhardt, JA; Meyers, JP; Niedzwiecki, D; Paul, J; Renfro, LA; Sargent, DJ; Saunders, M; Shi, Q; Shields, AF; Sobrero, AF; Souglakos, J; Taieb, J; Torri, V; Vernerey, D; Watanabe, T; Yamanaka, T; Yoshino, T, 2018)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."2.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
" Follow-up for potential delayed adverse effects and efficacy is ongoing."2.74Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009)
"Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP."2.72FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006)
"courses in 15 patients with cancer of different origins."2.68Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. ( Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM, 1995)
"Radiation complications included pneumonitis three of 30 (10%) and esophagitis (27%)."2.66Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989)
"Pretreatment with allopurinol did not reduce the toxicity of 5-FU administered as an intravenous bolus."2.65Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection. ( Howell, SB; Pfeifle, CE; Wung, WE, 1983)
"5-Fluorouracil (5-FU) is an analogue of pyrimidine nucleosides that is widely used in the treatment of head and neck, breast, ovarian, and colon cancer."2.40Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Pater, A; Shehata, N; Tang, SC, 1999)
"These neurologic disorders can be either metastatic to the brain, spinal cord, leptomeninges, or peripheral nerves or nonmetastatic including infections, vascular problems, metabolic abnormalities, side effects of therapy, or paraneoplastic syndromes."2.37Neurologic complications of systemic cancer. ( Patchell, RA; Posner, JB, 1985)
" 5-Fluorouracil at high dosage may cause cerebellar ataxia, but may also do so at low dosage when combined with thymidine infusions."2.37Neurological complications of antineoplastic therapy. ( Shapiro, WR; Young, DF, 1984)
"Fluorouracil (5-FU) is a commonly used chemotherapeutic agent in many cancers."1.625-Fluorouracil associated neurovascular toxicities. ( Dumas, B; Horta, L; Ozer, M; Sadrzadeh, H, 2021)
"Alopecia was observed in 60% of patients."1.62Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases. ( Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A, 2021)
"Our analysis confirms that women with colon cancer receiving adjuvant fluoropyrimidine-based chemotherapy are at increased risk of toxicity."1.62Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021)
" Adverse events occurred in 88."1.56Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. ( Arsenic, R; Dal Buono, A; Denecke, T; Jann, H; Merola, E; Pape, UF; Pavel, ME; Wiedenmann, B, 2020)
" Toxicity over four cycles was graded according to NCI Common Toxicity Criteria V2 or V3 (Common Terminology Criteria for Adverse Events, National Cancer Institute, Bethesda, MD)."1.43Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. ( Ali, R; Assenat, E; Baracos, VE; Bianchi, L; Mollevi, C; Roberts, S; Sawyer, MB; Senesse, P, 2016)
" This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events."1.40Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014)
"Uracil plus tegafur was shown to be less toxic than the drug alone in all the species, and uracil was found to decrease the toxicity of tegafur."1.27Effect of coadministration of uracil on the toxicity of tegafur. ( Haruno, A; Kunimune, Y; Morita, K; Unemi, N; Yamamoto, J; Yamashita, K; Yoshimura, Y, 1984)
"Among 26 colorectal cancer patients assessable for response there was a 15."1.26Allopurinol modulation of fluorouracil toxicity. ( Fox, RM; Piper, AA; Sampson, D; Tattersall, MH; Woods, RL, 1981)
" Although the neurotoxic effects produced by different cytostatics present a different appearance and are partly of only sporadic or slight clinical importance, there is hardly a cytostatic which does not exercise a side effect on the nervous system."1.26[Neurotoxic side effects of cytostatic therapy (author's transl)]. ( Maurach, R; Strian, F, 1981)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-199017 (33.33)18.7374
1990's8 (15.69)18.2507
2000's11 (21.57)29.6817
2010's9 (17.65)24.3611
2020's6 (11.76)2.80

Authors

AuthorsStudies
Iimura, Y1
Kurokawa, T1
Nojima, M1
Kanemoto, Y1
Yazawa, K1
Tsurita, G1
Kuroda, S1
Ron, DA1
Vera, R1
Labandeira, CM1
Manrique, MCA1
Núñez, MÁ1
Cid, NG1
Mata, JG1
Montes, AF1
Merola, E1
Dal Buono, A1
Denecke, T1
Arsenic, R1
Pape, UF1
Jann, H1
Wiedenmann, B1
Pavel, ME1
Wagner, AD1
Grothey, A2
Andre, T4
Dixon, JG1
Wolmark, N2
Haller, DG1
Allegra, CJ2
de Gramont, A3
VanCutsem, E1
Alberts, SR1
George, TJ1
O'Connell, MJ2
Twelves, C1
Taieb, J2
Saltz, LB1
Blanke, CD1
Francini, E2
Kerr, R2
Yothers, G2
Seitz, JF1
Marsoni, S1
Goldberg, RM2
Shi, Q2
Ben Nasr, S1
Zribi, A1
Ben Hassen, M1
Doghri, Y1
Ben Abdallah, I1
Trigui, E1
Fendri, S1
Ayari, J1
Balti, M1
Haddaoui, A1
Ozer, M1
Dumas, B1
Horta, L1
Sadrzadeh, H1
Sobrero, AF1
Shields, AF1
Yoshino, T1
Paul, J1
Souglakos, J1
Labianca, R1
Meyerhardt, JA1
Vernerey, D1
Yamanaka, T1
Boukovinas, I1
Meyers, JP1
Renfro, LA1
Niedzwiecki, D1
Watanabe, T1
Torri, V1
Saunders, M1
Sargent, DJ1
Iveson, T1
Cohen, PR1
Tonyali, O1
Benekli, M1
Berk, V1
Coskun, U1
Ozkan, M1
Yildiz, R1
Ucgul, E1
Sevinc, A1
Uncu, D1
Demirci, U1
Buyukberber, S1
Hamza, S1
Bouvier, AM1
Rollot, F1
Lepage, C1
Faivre, J1
Bedenne, L1
Ko, AH1
LoConte, N1
Tempero, MA1
Walker, EJ1
Kate Kelley, R1
Lewis, S1
Chang, WC1
Kantoff, E1
Vannier, MW1
Catenacci, DV1
Venook, AP1
Kindler, HL1
Matsuda, C1
Honda, M1
Tanaka, C1
Fukunaga, M1
Ishibashi, K1
Munemoto, Y1
Hata, T1
Bando, H1
Oshiro, M1
Kobayashi, M1
Tokunaga, Y1
Fujii, A1
Nagata, N1
Oba, K1
Mishima, H1
Ali, R1
Baracos, VE1
Sawyer, MB1
Bianchi, L1
Roberts, S1
Assenat, E1
Mollevi, C1
Senesse, P1
Fujii, C1
Anami, S1
Fujino, M1
Yasui, Y1
Fujita, M1
Inoue, M1
Nakayama, T1
Kamigaki, S1
Tatsuta, M1
Furukawa, H1
Sharif, S1
Colangelo, LH1
Lopa, SH1
Petrelli, NJ1
Atkins, JN2
Seay, TE1
Fehrenbacher, L1
O'Reilly, S1
Chu, L1
Azar, CA1
Kanai, M1
Yoshioka, A1
Tanaka, S1
Nagayama, S1
Matsumoto, S1
Nishimura, T1
Niimi, M1
Teramukai, S1
Takahashi, R1
Mori, Y1
Kitano, T1
Ishiguro, H1
Yanagihara, K1
Chiba, T1
Fukushima, M1
Matsuda, F1
Karachaliou, N1
Ziras, N1
Syrigos, K1
Tryfonidis, K1
Papadimitraki, E1
Kontopodis, E1
Bozionelou, V1
Kalykaki, A1
Georgoulias, V1
Mavroudis, D1
Sucker, C1
Lambers, C1
Stockschläder, M1
Dölken, G1
Louvet, C2
Carrat, F1
Mal, F1
Mabro, M2
Beerblock, K1
Vaillant, JC1
Cady, J1
Gamelin, E1
Chang, HM1
Kim, TW1
Ryu, BY1
Choi, SJ1
Park, YH1
Lee, JS1
Kim, WK1
Kang, YK1
Petrioli, R1
Paolelli, L1
Marsili, S1
Civitelli, S1
Cioppa, T1
Roviello, F1
Nettuno, R1
Intrivici, C1
Tanzini, G1
Lorenzi, M1
Francini, G1
Wang, WS1
Lin, JK1
Lin, TC1
Chen, WS1
Jiang, JK1
Wang, HS1
Chiou, TJ1
Liu, JH1
Yen, CC1
Chen, PM1
Ota, K1
Kishida, S1
Singer, Z1
Kozaczka, A1
Wilk, J1
Janas, J1
Howell, SB1
Pfeifle, CE1
Wung, WE1
Shapiro, WR1
Young, DF1
Yamamoto, J1
Haruno, A1
Yoshimura, Y1
Unemi, N1
Kunimune, Y1
Yamashita, K1
Morita, K1
Fox, RM1
Woods, RL1
Tattersall, MH1
Piper, AA1
Sampson, D1
Kish, JA1
Weaver, A1
Jacobs, J1
Cummings, G1
Al-Sarraf, M1
Strian, F2
Maurach, R2
Vexler, AM1
Mou, X1
Gabizon, AA1
Gorodetsky, R1
Cvitkovic, FB1
Haie-Meder, C1
Papadimitrakopoulou, V1
Armand, JP1
Cioloca, C1
Maugis, N1
Constans, JP1
Johnson, DH1
Paul, D1
Hande, KR1
Shehata, N1
Pater, A1
Tang, SC1
Fabian, A1
Maindrault-Goebel, F1
Carola, E1
Gilles, V1
Lotz, JP1
Tournigand, C1
Molitor, JL1
Artru, P1
Izrael, V1
Krulik, M1
Choi, SM1
Lee, SH1
Yang, YS1
Kim, BC1
Kim, MK1
Cho, KH1
Osterlund, P1
Elomaa, I1
Virkkunen, P1
Joensuu, H1
Harvey, HJ1
MacEwen, EG1
Hayes, AA1
Henness, AM1
Theilen, GH1
Madewell, BR1
Crow, SE1
Valdivieso, M1
Bodey, GP1
Gottlieb, JA1
Freireich, EJ1
Kuzuhara, S1
van der Hoop, RG1
van der Burg, ME1
ten Bokkel Huinink, WW1
van Houwelingen, C1
Neijt, JP1
Moore, DH1
Fowler, WC1
Crumpler, LS1
Vukelja, SJ1
Lombardo, FA1
James, WD1
Weiss, RB1
Lokich, J1
Chaffey, J1
Neptune, W1
Patchell, RA1
Posner, JB1
Weiss, HD1
Walker, MD1
Wiernik, PH1
Ahmann, DL1
Bisel, HF1
Hahn, RG1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620]100 participants (Anticipated)Interventional2023-06-20Not yet recruiting
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446]Phase 256 participants (Actual)Interventional2020-05-27Active, not recruiting
Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028]Phase 2100 participants (Actual)Interventional2011-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

10 reviews available for fluorouracil and Nervous System Disorders

ArticleYear
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Ca

2020
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil.
    Dermatology online journal, 2018, Apr-15, Volume: 24, Issue:4

    Topics: Administration, Cutaneous; Aged; Angioedema; Antimetabolites, Antineoplastic; Cheilitis; Fluorouraci

2018
[Neurotoxicity of 5-fluorouracil].
    Deutsche medizinische Wochenschrift (1946), 2002, Sep-27, Volume: 127, Issue:39

    Topics: Antimetabolites, Antineoplastic; Cerebellar Ataxia; Fluorouracil; Humans; Leukoencephalopathy, Progr

2002
[Drug-induced leukoencephalopathy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Aug-10, Volume: 96, Issue:8

    Topics: Antineoplastic Agents; Brain Edema; Cisplatin; Cytarabine; Fluorouracil; Humans; Hypertensive Enceph

2007
Neurological complications of antineoplastic therapy.
    Acta neurologica Scandinavica. Supplementum, 1984, Volume: 100

    Topics: Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemother

1984
[Cytostatic therapy: neurologic and psychiatric syndromes].
    Medizinische Klinik, 1980, Jun-20, Volume: 75, Issue:13

    Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Doxoru

1980
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
    Cancer investigation, 1999, Volume: 17, Issue:3

    Topics: Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Male; Middle Aged; Nerv

1999
[Neurological disorders induced by antineoplastic drugs].
    No to shinkei = Brain and nerve, 1992, Volume: 44, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Fluorouracil; Humans; Methotrexate; Nervou

1992
Neurologic complications of systemic cancer.
    Neurologic clinics, 1985, Volume: 3, Issue:4

    Topics: Arachnoid; Bacterial Infections; Brain; Brain Neoplasms; Cerebrovascular Disorders; Cisplatin; Disse

1985
Neurotoxicity of commonly used antineoplastic agents (first of two parts).
    The New England journal of medicine, 1974, 07-11, Volume: 291, Issue:2

    Topics: Animals; Antineoplastic Agents; Asparaginase; Brain; Brain Diseases; Fluorouracil; Humans; Leukemia;

1974

Trials

17 trials available for fluorouracil and Nervous System Disorders

ArticleYear
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    The New England journal of medicine, 2018, Mar-29, Volume: 378, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    The New England journal of medicine, 2018, Mar-29, Volume: 378, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    The New England journal of medicine, 2018, Mar-29, Volume: 378, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    The New England journal of medicine, 2018, Mar-29, Volume: 378, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2018
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea

2013
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
    Pancreas, 2016, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin;

2016
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
    International journal of clinical oncology, 2016, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jul-10, Volume: 27, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg

2012
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo

2005
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
    Oncology, 2006, Volume: 70, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2006
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis

2007
Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
    Cancer, 1983, Jan-15, Volume: 51, Issue:2

    Topics: Allopurinol; Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Humans; Inflammation; Leukocyt

1983
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.
    International journal of cancer, 1995, Mar-03, Volume: 60, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin;

1995
Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.
    Journal of neuro-oncology, 1993, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined

1993
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluo

1997
[Evaluation of nervous system disorders during the course of gastric carcinoma on the basis of clinical electrophysiologic analysis].
    Annales Academiae Medicae Stetinensis, 1999, Volume: 45

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Chemotherapy, Ad

1999
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2000
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    Cancer, 1990, Oct-15, Volume: 66, Issue:8

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1990
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
    Cancer, 1989, Sep-01, Volume: 64, Issue:5

    Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit

1989

Other Studies

24 other studies available for fluorouracil and Nervous System Disorders

ArticleYear
Potential thiamine deficiency and neurological symptoms in patients receiving chemotherapy for gastrointestinal cancer.
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Folic Acid; G

2020
Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Pancreas, 2020, Volume: 49, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil

2020
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
    Journal of the National Cancer Institute, 2021, 04-06, Volume: 113, Issue:4

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit

2021
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
    Bulletin du cancer, 2021, Volume: 108, Issue:3

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases

2021
5-Fluorouracil associated neurovascular toxicities.
    Current problems in cancer, 2021, Volume: 45, Issue:6

    Topics: Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous Sys

2021
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
    Annals of surgical oncology, 2014, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla

2014
Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens.
    Cancer medicine, 2016, Volume: 5, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surfac

2016
[Management of hand-foot syndrome in patient treated with capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil

2008
Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
    Cancer epidemiology, 2010, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2010
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
    Cancer investigation, 2003, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2003
[Non-hematologic adverse effects of cytostatic drugs].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1984, Nov-19, Volume: 39, Issue:47

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female;

1984
Effect of coadministration of uracil on the toxicity of tegafur.
    Journal of pharmaceutical sciences, 1984, Volume: 73, Issue:2

    Topics: Animals; beta-Alanine; Cats; Dogs; Female; Fluorouracil; Heart Diseases; Lethal Dose 50; Male; Mice;

1984
Allopurinol modulation of fluorouracil toxicity.
    Cancer chemotherapy and pharmacology, 1981, Volume: 5, Issue:3

    Topics: Allopurinol; Drug Eruptions; Drug Therapy, Combination; Fluorouracil; Hematologic Diseases; Humans;

1981
Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Squamous Ce

1984
[Neurotoxic side effects of cytostatic therapy (author's transl)].
    Fortschritte der Neurologie-Psychiatrie, 1981, Volume: 49, Issue:4

    Topics: Antineoplastic Agents; Asparaginase; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Doxoru

1981
5-fluorouracil-induced leukoencephalopathy in patients with breast cancer.
    Journal of Korean medical science, 2001, Volume: 16, Issue:3

    Topics: Adenocarcinoma, Mucinous; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Brain; Breast Neop

2001
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
    Oncology, 2001, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2001
Neurotoxicosis associated with use of 5-fluorouracil in five dogs and one cat.
    Journal of the American Veterinary Medical Association, 1977, Aug-01, Volume: 171, Issue:3

    Topics: Animals; Ataxia; Blindness; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Male; Nerv

1977
Neurotoxicosis associated with use of 5-florouracil.
    Journal of the American Veterinary Medical Association, 1977, Oct-15, Volume: 171, Issue:8

    Topics: Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Fluorouracil; Nervous System Diseases

1977
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
    Cancer research, 1976, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise

1976
5-Fluorouracil neurotoxicity.
    Gynecologic oncology, 1990, Volume: 36, Issue:1

    Topics: Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Middle Aged; Nervous System Diseases;

1990
Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.
    Annals of internal medicine, 1989, Oct-15, Volume: 111, Issue:8

    Topics: Dermatitis, Exfoliative; Fluorouracil; Hand Dermatoses; Humans; Male; Middle Aged; Nervous System Di

1989
Fluorouracil and the palmar-plantar erythrodysesthesia syndrome.
    Annals of internal medicine, 1985, Volume: 102, Issue:3

    Topics: Dermatitis, Exfoliative; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Middle Aged

1985
A phase 2 evaluation of 1-(2-chloroethyl)-3-(4- methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast cancer.
    Cancer research, 1974, Volume: 34, Issue:1

    Topics: Alopecia; Blood Platelets; Breast Neoplasms; Castration; Cyclohexanes; Cyclophosphamide; Drug Evalua

1974